RecruitingNCT06792721
MEASUREMENT OF CIRCULATING MUTATION BURDEN
EVALUATION OF CANCER RISK BY MEASUREMENT OF CIRCULATING MUTATIONAL BURDEN IN CARRIERS OF A GENETIC PREDISPOSITION
Sponsor
Centre Francois Baclesse
Enrollment
30 participants
Start Date
Jul 4, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
Cancer-free women with a hereditary predisposition to breast and/or ovarian cancer
Eligibility
Sex: FEMALEMin Age: 30 YearsMax Age: 50 Years
Inclusion Criteria7
- Female participant
- Participant undergoing oncogenetic follow-up at the Centre François Baclesse
- Participant belonging to a pair of related biological siblings
- Within the sibling pair, one participant is a carrier of a hereditary predisposition linked to a BRCA1/2 mutation (case), and the other participant is not a carrier (control).
- Participant between 30 and 50 years of age
- Participant affiliated to a social security scheme
- Participant having given her consent to participate by signing an informed consent form prior to any specific study-related procedure.
Exclusion Criteria1
- \-
Interventions
GENETICMutation Burden cfMB analysis
Blood samples will be collected (one time only)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06792721
Related Trials
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
NCT06418204467 locations
The Vanguard Study: Testing a New Way to Screen for Cancer
NCT0699589836 locations
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
NCT059415204 locations
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
NCT0618475011 locations
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
NCT061953063 locations